General anesthesia administered
through inhalation route is categorized as IH anesthetics and is used for
maintaining sedative stage during surgical procedure. IH drugs are preferred
for pediatric and geriatric surgery.
The global General
Anesthesia Drugs Market is estimated to account for US$ 5999.7 Mn in terms
of value by the end of 2027.
Global General Anesthesia Drugs
Market: Drivers
Increasing prevalence of chronic
renal disease (CRD) is expected to boost growth of the global General
Anesthesia Drugs market over the forecast period. For instance, according to
European Renal Association – European Dialysis and Transplant Association’s data
in 2018, over 850 million people worldwide have some form of kidney disease
Global General Anesthesia Drugs
Market: Opportunities
Increasing R&D in general
anesthesia is expected to offer to offer lucrative growth opportunities for
market players. For instance, in October 2019, a study published in the Journal
of the American Medical Association (JAMA) by researchers from Aarhus
University Hospital found that the use of protocol-based general anaesthesia in
acute ischaemic stroke patients undergoing thrombectomy was significantly
associated with less disability at three-months, compared with procedural
sedation.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/524
Global General Anesthesia Drugs
Market: Restraints
However, lack of skilled
anesthetists and nurse anaesthetist is expected to hamper growth of the global
General Anesthesia Drugs market.
Key Takeaways:
The Propofol segment in the
global General Anesthesia Drugs market was valued at US$ 1,300.6 Mn in 2018 and
is expected to reach US$ 2127.9 Mn by 2025 at a CAGR of 5.7% during the
forecast period.The growth of the segment is attributed to increasing incidence
and prevalence of chronic diseases.
Market Trends
Key players in the market are
focused on product development and approval to expand their product portfolio.
For instance, in October 2019, SunGen Pharmaceuticals, a privately held
specialty pharmaceutical company, received its eighth ANDA approval from the US
Food and Drug Administration (FDA) for Lidocaine Ointment USP used for
production of anesthesia of accessible mucous membranes of the oropharynx.
Use of ketamine has increased as
a pain management alternative due to the opioid epidemic in the U.S. However,
use of ketamine is also associated with side effects such as hallucinations and
visual disturbances.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/general-anesthesia-drugs-market-524
Global General Anesthesia Drugs
Market: Competitive Landscape
Major players operating in the
global General Anesthesia Drugs market include, Baxter International Inc.,
AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA,
and Hospira Inc.
Global General Anesthesia Drugs
Market: Key Developments
Key players in the market are
focused on adopting partnership strategies to expand their product portfolio.
For instance, in December 2019, Nephron Pharmaceuticals Corporation partnered
with National Medical Products Inc. to offers patients quality care through virtually
pain-free anesthetics.
Key players in the market are
focused on adopting MA& strategies to expand their product portfolio. For
instance, in November 2019, Sandoz, the generics unit of Novartis, acquired
Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings to expand
its presence in Asia Pacific. Aspen offers off-patent branded medicines with a
focus on anesthetics and specialty brands.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/524
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment